Health

HbA1c Calculator: Convert A1c to Estimated Average Glucose (eAG)

Calculator Free · Private

Data updated: Jun 4, 2026 · Source: Nathan DM et al. Diabetes Care 2008 / ADA Standards of Care 2026

Reviewed by: Martín Rodríguez (editorial policy ) · Last reviewed: Jun 4, 2026

Was this calculator helpful?

Hemoglobin A1c (HbA1c, glycated hemoglobin) reflects your average blood glucose over the prior 8 to 12 weeks — a rolling average that captures both fasting and postprandial excursions you would miss with a single fasting test. It forms when glucose in the bloodstream binds non-enzymatically to the beta chain of adult hemoglobin (HbA); because red blood cells circulate for roughly 90–120 days, the percentage of glycated hemoglobin integrates intra-day glycemic variation across that entire window. This calculator converts your A1c into estimated average glucose (eAG) using the ADAG regression equation (Nathan et al., Diabetes Care 2008), validated with continuous glucose monitoring data from 507 subjects: eAG (mg/dL) = 28.7 × A1c − 46.7. It also classifies your result per ADA 2026 diagnostic criteria: Normal (< 5.7%), Prediabetes (5.7–6.4%), or Diabetes (≥ 6.5%). YMYL disclaimer: This result is an educational tool. For diagnosis, medication changes, or clinical interpretation, always consult your physician or endocrinologist.

Last reviewed: June 3, 2026 Verified by Martín Rodríguez Source: Nathan DM et al. — Translating the A1C Assay Into Estimated Average Glucose Values. Diabetes Care 2008;31(8):1473–1478, ADA — Standards of Care in Diabetes 2026 (Section 2: Diagnosis and Classification), ADA — eAG/A1C Conversion Calculator (Professional Resources), NIDDK — A1C Test (National Institute of Diabetes and Digestive and Kidney Diseases), CDC — All About Your A1C 100% private

HbA1c (glycated hemoglobin) reflects your average blood glucose over the past 2–3 months. ADA 2026 ranges: Normal < 5.7% — Prediabetes 5.7–6.4% — Diabetes ≥ 6.5%. To convert A1c to estimated average glucose: eAG (mg/dL) = 28.7 × A1c(%) − 46.7. Example: A1c 7.0% → eAG 154 mg/dL (8.5 mmol/L). Target for most adults with type 2 diabetes: A1c < 7%.

When to use this calculator

Adult receiving their first A1c result (e.g., 6.8%) who wants to understand what average daily glucose it represents and whether they have diabetes.
Type 2 diabetes patient on metformin who wants to compare their quarterly A1c (7.3%) with the ADA 2026 target and see exactly how much reduction is needed.
Patient who started a GLP-1 (semaglutide, dulaglutide, tirzepatide) and wants to project what their new A1c would be after an expected 1.5–2.0 percentage point reduction.
Clinician explaining to a patient what A1c 8.5% means in terms of daily average glucose (~197 mg/dL) to motivate treatment adherence.

Example: A1c 7.0%

Lab A1c: 7.0%
eAG (mg/dL) = 28.7 × 7.0 − 46.7 = 200.9 − 46.7 = 154.2 mg/dL
eAG (mmol/L) = 1.59 × 7.0 − 2.59 = 11.13 − 2.59 = 8.54 mmol/L
ADA 2026 classification: Diabetes (≥ 6.5%)
vs. ADA 2026 target: Within goal for general adult T2D (< 7%)

Result: A1c 7.0% → eAG 154 mg/dL (8.5 mmol/L) — Diabetes, at ADA 2026 target (< 7%). Every 1 percentage point reduction in A1c lowers estimated average glucose by approximately 28.7 mg/dL.

How it works

3 min read

How HbA1c Reflects Your Average Glucose

Hemoglobin A1c forms when glucose in the bloodstream binds non-enzymatically to the beta chain of adult hemoglobin (HbA). Because red blood cells circulate for roughly 90–120 days, the percentage of glycated hemoglobin gives a weighted time-average of plasma glucose over the prior 8 to 12 weeks — with the most recent 30 days contributing approximately 50% of the A1c value, the prior 30–60 days contributing about 25%, and the 60–120 day window the remaining 25%. This is why a new GLP-1 prescription or dietary change takes 6–12 weeks to fully register in A1c.

How It Works: The Nathan ADAG Formula

David Nathan and the A1c-Derived Average Glucose (ADAG) Study Group published the regression equation in Diabetes Care (2008), based on continuous glucose monitoring from 507 participants (type 1, type 2, and non-diabetic). The ADA endorses this conversion for patient education:

eAG (mg/dL)  = 28.7 × A1c(%) − 46.7
eAG (mmol/L) = 1.59 × A1c(%) − 2.59

eAG Reference Table (Nathan Formula)

A1c (%)	eAG (mg/dL)	eAG (mmol/L)	ADA 2026 classification
5.0	97	5.4	Normal
5.7	117	6.5	Prediabetes threshold
6.0	126	7.0	Prediabetes
6.5	140	7.8	Diabetes diagnostic threshold
7.0	154	8.6	General T2D ADA target ceiling
8.0	183	10.2	Above goal — intensify therapy
9.0	212	11.8	Markedly uncontrolled
10.0	240	13.4	Very high — accelerated complication risk
12.0	298	16.5	Critical — urgent intervention needed

ADA 2026 Diagnostic Criteria

Category	A1c	Recommended action
Normal	< 5.7%	Annual screening if risk factors present
Prediabetes	5.7–6.4%	Lifestyle intervention; metformin if BMI ≥35 or age < 60
Diabetes	≥ 6.5%	Confirm with repeat test; initiate treatment

A1c Targets by Clinical Profile (ADA 2026)

Profile	A1c target
General nonpregnant adults with T2D	< 7%
Older adults with multiple comorbidities	< 8%
Recent diagnosis, long life expectancy	< 6.5% (if achievable without hypoglycemia)
Preexisting T1D or T2D in pregnancy	< 6% (or < 6.5% if hypoglycemia risk)
Children and adolescents with T1D	< 7%

Accuracy Limitations and Hemoglobinopathies

A1c assumes a normal red blood cell lifespan. Several conditions distort the result:

Sickle cell trait or disease (HbS), HbC, HbD, HbE: most modern HPLC and immunoassay methods are hemoglobinopathy-tolerant, but boronate affinity is preferred.

Thalassemia, hemolytic anemia, recent blood transfusion: shortened red cell lifespan falsely lowers A1c.

Iron deficiency anemia, B12/folate deficiency: longer cell lifespan falsely elevates A1c by 0.3–0.5 points.

Chronic kidney disease stage 4–5, dialysis: erythropoietin therapy and reduced red cell survival lower A1c — use fructosamine or CGM instead.

Pregnancy: increased red cell turnover lowers A1c by ~0.3–0.5 points — use the 2-hour 75g OGTT for gestational diabetes screening.

Time-in-Range (TIR) and Its Relationship to A1c

Continuous glucose monitoring (CGM) provides Time-in-Range (TIR) — the percentage of time between 70–180 mg/dL. A TIR of 70% approximates A1c ≈ 7%; every 10% TIR improvement correlates with an A1c reduction of ~0.5% (Beck et al., Diabetes Care 2019). TIR captures hypoglycemic excursions and glycemic variability that A1c cannot distinguish — making them complementary metrics.

Impact of GLP-1 Receptor Agonists and SGLT2 Inhibitors on A1c

Semaglutide 1.0–2.4 mg (Ozempic/Wegovy): typically −1.5 to −1.8 percentage points within 26 weeks.

Tirzepatide 5–15 mg (Mounjaro/Zepbound): up to −2.4 points (SURPASS trials) — plus 15–20% body weight reduction.

SGLT2 inhibitors (empagliflozin, dapagliflozin): −0.5 to −1.0 point, with independent cardiovascular and renal protection.

ADA 2026 recommends GLP-1 RAs or SGLT2 inhibitors as first-line add-ons in patients with established ASCVD, heart failure, or CKD — regardless of current A1c level.

Editorial Note

This calculator is an educational tool. Clinical decisions — diagnosis, treatment initiation, dose titration — belong with your endocrinologist or primary care clinician. A single A1c is a screening or monitoring result; diabetes diagnosis requires confirmation per the criteria above.

Frequently asked questions

What is a normal A1c level?

Per ADA 2026: Normal is A1c < 5.7%; Prediabetes is 5.7–6.4%; Diabetes is ≥ 6.5%. For older adults (65+) with multiple comorbidities or limited life expectancy, an individualized target of < 8% is acceptable to avoid hypoglycemia. Children and adolescents with type 1 diabetes target < 7%. These thresholds apply to venous lab samples using NGSP/IFCC-standardized assays — not point-of-care devices for diagnostic purposes.

How do I convert my A1c to an average blood sugar (eAG)?

Use the Nathan ADAG formula: eAG (mg/dL) = 28.7 × A1c(%) − 46.7 or eAG (mmol/L) = 1.59 × A1c(%) − 2.59. Examples: A1c 6.5% → eAG 140 mg/dL (7.8 mmol/L); A1c 7.0% → eAG 154 mg/dL (8.5 mmol/L); A1c 8.0% → eAG 183 mg/dL (10.2 mmol/L). Every 1 percentage point change in A1c equals approximately 28.7 mg/dL change in average glucose.

Can prediabetes (A1c 5.7–6.4%) be reversed?

Yes. The Diabetes Prevention Program (DPP, NEJM 2002) showed that 7% weight loss + 150 minutes/week of moderate-intensity aerobic exercise reduces progression to type 2 diabetes by 58% over 3 years — more effective than metformin (31%). Metformin is recommended for prediabetic patients under 60 with BMI ≥35 or a history of gestational diabetes. Many people normalize their A1c within 6–12 months with sustained lifestyle change.

Why does my A1c not match my fasting glucose readings?

A1c reflects 90-day average glucose; fasting plasma glucose is a single time point. Discrepancies suggest: (1) postprandial hyperglycemia not captured by morning fasting (consider CGM or postprandial finger-sticks), (2) shortened or lengthened red blood cell lifespan distorting A1c (anemia, hemoglobinopathy, CKD), or (3) recent rapid glycemic change not yet reflected in A1c. If discrepancy persists, your endocrinologist may order fructosamine or glycated albumin.

Does anemia affect A1c accuracy?

Yes, substantially. Iron deficiency anemia, vitamin B12/folate deficiency, and aplastic anemia lengthen red cell lifespan and falsely elevate A1c by approximately 0.3–0.5 percentage points. Conversely, hemolytic anemia, recent blood transfusion, thalassemia, and chronic kidney disease with erythropoietin therapy shorten red cell lifespan and falsely lower A1c. In these scenarios, fructosamine (2–3 week glucose average) or CGM-derived time-in-range are more reliable.

How much can GLP-1 medications lower my A1c?

Semaglutide 1.0–2.4 mg (Ozempic, Wegovy) typically reduces A1c by 1.5–1.8 percentage points within 26 weeks. Tirzepatide 5–15 mg (Mounjaro, Zepbound), a dual GIP/GLP-1 agonist, achieves up to 2.4-point reductions in the SURPASS trials, plus 15–20% body weight loss. SGLT2 inhibitors (empagliflozin, dapagliflozin) lower A1c by 0.5–1.0 points and add independent cardiovascular and renal protection. Effects plateau around 6–12 months.

How often should I get an A1c test?

ADA 2026: Every 3 months if not at glycemic goal or after any therapy change (new medication, dose titration). Every 6 months when stably at target with no recent therapy changes. Annually for adults with confirmed prediabetes (or every 6 months if high-risk). For type 1 diabetes: quarterly testing is standard. Pregnancy-complicated diabetes requires more frequent monitoring with CGM.

Is time-in-range (TIR) a better measure than A1c?

TIR (percent of time with glucose 70–180 mg/dL on CGM) captures what A1c misses: hypoglycemia frequency, glycemic variability, and postprandial spikes — all independent predictors of microvascular complications. The 2025 international consensus (Battelino et al.) supports TIR ≥ 70% as a primary target for most people with diabetes using CGM. A1c remains the validated endpoint for diagnosis and large-scale outcome trials. For day-to-day management, TIR and A1c are now considered complementary: approximately TIR 70% ≈ A1c 7%.

Can steroids or illness raise my A1c?

Acute illness, infection, surgery, and corticosteroids (prednisone, dexamethasone) elevate blood glucose for days to weeks. If sustained, this will raise A1c. Glucocorticoid-induced hyperglycemia is dose-dependent and usually reversible after tapering. Always disclose all medications — including over-the-counter steroids, antipsychotics (olanzapine, clozapine), and immunosuppressants — to your clinician before A1c interpretation.